G0S2 and chronic myelogenous leukemia, BCR-ABL1 positive: As lipid‐modifying drugs were recently shown to enhance molecular response in CML patients on TKI therapy,86 our data suggest that restoring G0S2 expression and/or lipid‐modifying drugs could have clinical utility by improving lipid homeostasis, promoting myeloid differentiation and reestablishing TKI sensitivity.